It is likely that CSL has a faster turnaround time for repeat donors given its rewards program that incentivizes donors to earn redeemable points. This would aid the volume of plasma collected per ...

A key benefit of this strategy is that it rewards patience ... largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...

CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...

“Plasma collections continue to grow with the cost of collections decreasing,’’ CSL said. “The roll out of the RIKA plasmapheresis devices in the US is well advanced and on track to ...

But don’t worry too much, CSL shareholders. Not for the first time, CSL’s core Behring plasma arm has come to the rescue with a rock-solid performance, led by its immunoglobulin products.